ArticleAbdominal radiology (New York)2025
MRI-derived extracellular volume to assess liver fibrosis in patients with metabolic-associated steatotic liver disease.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cross-Vendor Validation of Proton Density Fat Fraction and TJournal of magnetic resonance imaging : JMRI · 2026Article
- New Treatment Options for MASLD Patients with Type 2 Diabetes.Life (Basel, Switzerland) · 2026Review
- "WBC-HBP Dissociation" Unveils Occult Xanthogranulomatous Inflammation Mimicking Hepatocellular Carcinoma in Diabetic Patients.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMetabolic associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and non-invasive fibrosis staging still represents a challenge. Our main objective was to estimate the degree of liver fibrosis in these patients using T1 mapping and the extracellular volume (ECV) by MRI in comparison with liver stiffness assessed by MR elastography (MRE).
methodsIn a single-center cross-sectional study, patients with MASLD were prospectively enrolled and underwent MRI with liver T1 mapping and ECV calculations. Groups with and without significant liver fibrosis assessed by MRE were compared with the Mann-Whitney test, chi-square test, and Fisher's exact test. Correlation analysis was conducted using Spearman's test, and a receiver operating characteristic (ROC) curve was generated to assess the ability of ECV to differentiate between groups.
resultsThis study evaluated 54 patients, 37% were men, with a mean age of 58.0 ± 12.0 years. Mild liver fibrosis (F0-F1) was present in 38 patients, and significant fibrosis (F2-F4) was detected in 16 patients. Patients with significant fibrosis presented higher native T1 (954 ± 126 vs. 820 ± 123; p < 0.001) and ECV (37.9% vs. 29.1%; p < 0.001) values than those with no/mild fibrosis. Liver stiffness was correlated with native T1 (r = 0.512, p < 0.001) and ECV (r = 0.443, p < 0.001). The native liver T1 and ECV differentiated patients with and without significant liver fibrosis on MRE (AUC = 0.85 and 0.84, respectively).
conclusionNative T1 and ECV show potential as an alternative method for the non-invasive staging of fibrosis in patients with MASLD, although further validation in larger cohorts is needed.
Indexed as
Identifiers
40246797What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.